Which of the mentioned drugs most commonly causes acute liver failure?
Drug-induced postural hypotension is seen with which of the following?
In a chronic alcoholic patient, all of the following drugs should be avoided except?
Which neuromuscular blocker releases histamine?
BAL (British anti-Lewisite, Dimercaprol) is of no value for the treatment of poisoning by which of the following?
A 25-year-old male hospitalized with a liver cyst due to Echinococcus granulosus refused surgery. Albendazole was used at a high dose for 3 months. This patient should be monitored for toxicity to which organ?
A two-year-old boy presents with fever for 3 days which responded to administration of paracetamol. Three days later he developed acute renal failure, marked acidosis and encephalopathy. His urine showed plenty of oxalate crystals. The blood anion gap and osmolar gap were increased. Which of the following is the most likely diagnosis?
Bupivacaine poisoning is treated with:
Which of the following conditions is caused by cadmium exposure?
What is the approved use of migalastat?
Explanation: **Explanation:** **Paracetamol (Acetaminophen)** is the most common cause of drug-induced acute liver failure (ALF) worldwide. At therapeutic doses, it is metabolized via glucuronidation and sulfation. However, in overdose, these pathways become saturated, and the drug is shunted to the **CYP2E1** pathway, producing a highly reactive toxic metabolite called **NAPQI** (*N-acetyl-p-benzoquinone imine*). Under normal conditions, NAPQI is neutralized by **glutathione**. When glutathione stores are depleted (below 30%), NAPQI causes oxidative stress and centrilobular hepatic necrosis. **Analysis of Incorrect Options:** * **Warfarin:** This is an oral anticoagulant that inhibits Vitamin K epoxide reductase. Its primary toxicity is **hemorrhage**, not hepatotoxicity. * **Tetracycline:** While high-dose intravenous tetracycline can cause **microvesicular steatosis** (fatty liver), it is a rare cause of fulminant acute liver failure in modern clinical practice compared to paracetamol. * **Valproate:** This anticonvulsant can cause idiosyncratic hepatotoxicity (especially in children under 2 years with metabolic disorders), but it is statistically less common than paracetamol-induced failure. **High-Yield Clinical Pearls for NEET-PG:** * **Antidote:** **N-acetylcysteine (NAC)** is the specific antidote; it acts by replenishing glutathione stores. * **Rumack-Matthew Nomogram:** Used to predict hepatotoxicity based on plasma paracetamol levels starting 4 hours post-ingestion. * **Alcohol Interaction:** Chronic alcohol consumption induces CYP2E1, increasing the risk of toxicity even at lower doses of paracetamol. * **Histology:** Paracetamol toxicity typically presents as **Zone 3 (centrilobular) necrosis**.
Explanation: **Explanation:** **Vitamin A toxicity (Hypervitaminosis A)** is the correct answer because chronic toxicity leads to significant autonomic dysfunction and vascular changes. While Vitamin A toxicity is classically associated with **Pseudotumor cerebri** (idiopathic intracranial hypertension), it also causes thinning of the blood vessel walls and interference with sympathetic vasomotor tone, which manifests clinically as **postural hypotension**. [2] **Analysis of Options:** * **Vitamin A toxicity:** Chronic ingestion leads to a constellation of symptoms including dry skin, hepatosplenomegaly, cortical thickening of bones, and autonomic instability leading to postural hypotension. [2] * **Methotrexate:** This folate antagonist primarily causes bone marrow suppression, mucositis, and hepatotoxicity. It is not associated with acute changes in blood pressure or postural stability. * **Aldomet (Alpha-methyldopa):** While this is a centrally acting antihypertensive, it is a common "distractor." Methyldopa reduces overall blood pressure but is specifically known for **sparing** the baroreceptor reflex, meaning it is *less* likely to cause postural hypotension compared to other antihypertensives like Prazosin. [3] * **Valproic acid:** Common side effects include weight gain, alopecia, tremors, and hepatotoxicity (V-A-L-P-R-O-A-T-E mnemonic). It does not typically affect orthostatic blood pressure. **NEET-PG High-Yield Pearls:** * **Most common drug class causing postural hypotension:** Alpha-blockers (e.g., Prazosin - "First dose phenomenon"), Diuretics, and TCAs. [1] * **Vitamin A Toxicity Triad:** Headache (Pseudotumor cerebri), Skin peeling (desquamation), and Bone pain/Hyperostosis. [2] * **Teratogenicity:** Isotretinoin (Vitamin A derivative) is highly teratogenic; a negative pregnancy test is mandatory before prescription.
Explanation: The core concept tested here is the **Disulfiram-like reaction**. Chronic alcoholics should avoid drugs that interfere with alcohol metabolism, specifically those that inhibit the enzyme **aldehyde dehydrogenase**. ### **Why Beclomethasone is the Correct Answer** **Beclomethasone** is a potent glucocorticoid used primarily in the management of asthma and allergic rhinitis. It does not interfere with alcohol metabolism, nor does it possess the chemical structure required to trigger a disulfiram-like reaction. Therefore, it is safe to use in a chronic alcoholic patient. ### **Why the Other Options are Incorrect** Options A, B, and C all cause a **Disulfiram-like reaction** when consumed with alcohol. This occurs because they inhibit aldehyde dehydrogenase, leading to an accumulation of acetaldehyde, which causes flushing, tachycardia, nausea, vomiting, and hypotension. * **Cefamandole (Option A):** A second-generation cephalosporin containing a **methylthiotetrazole (MTT) side chain**. This specific side chain is responsible for inhibiting aldehyde dehydrogenase. * **Metronidazole (Option B):** A classic nitroimidazole antibiotic known for causing severe disulfiram-like reactions; patients are routinely advised to avoid alcohol for 48–72 hours after the last dose. * **Chlorpropamide (Option C):** A first-generation sulfonylurea. Among diabetes medications, it is the most notorious for causing "Chlorpropamide-alcohol flushing." ### **High-Yield Clinical Pearls for NEET-PG** * **Mnemonic for Disulfiram-like drugs:** "**C**an **M**any **G**uys **P**lay **T**ennis?" (**C**ephalosporins with MTT chain like Cefotetan/Cefamandole, **M**etronidazole/Tinidazole, **G**riseofulvin, **P**rocarbazine, **T**olbutamide/Chlorpropamide). * **MTT Side Chain:** Also responsible for causing **Hypoprothrombinemia** (bleeding tendency) by inhibiting Vitamin K epoxide reductase. * **Management:** Treatment of a disulfiram-like reaction is primarily supportive (IV fluids and antiemetics).
Explanation: ### Explanation **Correct Answer: B. Atracurium** **Mechanism and Histamine Release:** Atracurium belongs to the **benzylisoquinolinium** class of non-depolarizing neuromuscular blockers (NMDBs). Drugs in this chemical class are notorious for causing the non-immunologic release of **histamine** from mast cells, especially when administered rapidly or in high doses. Clinical manifestations of this histamine release include flushing, hypotension, tachycardia, and occasionally bronchospasm. **Analysis of Incorrect Options:** * **A. Pancuronium:** This is an aminosteroid NMDB. It does not cause histamine release but is known for its **vagolytic effect**, leading to tachycardia and hypertension. * **C. Vecuronium:** An aminosteroid derivative of pancuronium. It is considered "cardiovascularly stable" because it lacks both histamine-releasing properties and vagolytic effects. * **D. Rocuronium:** Another aminosteroid. Like vecuronium, it does not typically release histamine, making it a preferred choice for patients with reactive airway disease or hemodynamic instability. **High-Yield NEET-PG Pearls:** 1. **Hofmann Elimination:** Atracurium and its isomer, **Cisatracurium**, undergo spontaneous molecular degradation in the plasma (Hofmann elimination). This makes them the **drugs of choice in liver and kidney failure**. 2. **Laudanosine Toxicity:** A metabolite of atracurium (laudanosine) can cross the blood-brain barrier and may cause **seizures** at high concentrations. 3. **Cisatracurium Advantage:** Unlike atracurium, cisatracurium is more potent and is associated with **minimal to no histamine release**, making it safer for asthmatic patients. 4. **Mivacurium:** Another benzylisoquinolinium that causes significant histamine release (shortest acting non-depolarizing agent).
Explanation: **Explanation:** **Dimercaprol (British Anti-Lewisite or BAL)** is a chelating agent developed during WWII as an antidote to Lewisite (an organic arsenical gas). It works by providing free sulfhydryl (-SH) groups that compete with the enzymes of the body for binding with heavy metals, forming stable, non-toxic, and excretable cyclic chelates [1]. **Why Selenium is the Correct Answer:** BAL is contraindicated or of no value in **Selenium** and **Cadmium** poisoning. In the case of Selenium, BAL can actually increase the toxicity of the metal by forming a complex that is more nephrotoxic than the metal itself. Therefore, it is avoided in these specific toxicities. **Analysis of Incorrect Options:** * **Arsenic:** BAL is the primary chelating agent for acute arsenic poisoning. It effectively binds trivalent arsenic, preventing it from inhibiting the pyruvate dehydrogenase complex. * **Mercury:** BAL is used for acute inorganic mercury poisoning [3]. However, it is ineffective (and potentially harmful) for chronic or organic mercury (methylmercury) poisoning as it may redistribute the metal to the brain [3]. * **Zinc:** While not the first-line treatment (calcium disodium EDTA is preferred), BAL can chelate zinc and is considered effective in cases of severe systemic zinc toxicity [2]. **High-Yield Clinical Pearls for NEET-PG:** * **Route of Administration:** BAL is highly lipid-soluble and must be administered via **deep intramuscular (IM)** injection in an oily (peanut oil) base [1]. * **Contraindications:** Avoid in patients with **peanut allergy**, severe hepatic insufficiency, and G6PD deficiency (risk of hemolysis). * **Urine pH:** It is most effective when the urine is alkaline, as the BAL-metal complex is unstable in acidic environments. * **Iron Interaction:** Never use BAL concurrently with Iron supplements, as the resulting complex is highly toxic.
Explanation: **Explanation:** **Albendazole**, a benzimidazole anthelmintic, is the drug of choice for Hydatid disease (*Echinococcus granulosus*). While short-term use (1–3 days) for intestinal worms is generally well-tolerated, **prolonged high-dose therapy** (as required for hydatid cysts or neurocysticercosis) is associated with significant systemic toxicity. 1. **Why Liver is the Correct Answer:** Albendazole undergoes extensive first-pass metabolism in the liver to its active metabolite, albendazole sulfoxide. Long-term administration frequently leads to an asymptomatic increase in **serum transaminases (ALT/AST)**. In some cases, it can cause severe hepatotoxicity or jaundice. Therefore, baseline and bi-weekly **Liver Function Tests (LFTs)** are mandatory during extended treatment cycles. 2. **Why Other Options are Incorrect:** * **Gonads:** While some animal studies suggested embryotoxicity (making it contraindicated in pregnancy), it is not typically associated with gonadal dysfunction or infertility in humans. * **Kidney:** Albendazole is not primarily nephrotoxic. Renal monitoring is not a standard requirement for this drug. * **Peripheral Nerves:** Neurotoxicity is not a side effect of albendazole. However, in neurocysticercosis, neurological symptoms may worsen due to the inflammatory response to dying parasites (managed with steroids). **NEET-PG High-Yield Pearls:** * **Mechanism of Action:** Inhibits microtubule synthesis by binding to **β-tubulin**, leading to glucose depletion and death of the parasite. * **Absorption:** Oral absorption is poor but increases significantly (up to 5x) when taken with a **fatty meal**. * **Other Major Toxicity:** **Bone marrow suppression** (leukopenia/pancytopenia) is the second most critical side effect to monitor via CBC. * **Drug of Choice:** Hydatid disease, Neurocysticercosis, Cutaneous Larva Migrans, and most intestinal nematodes (Ascaris, Hookworm, Enterobius).
Explanation: **Explanation:** The clinical presentation is classic for **Diethylene Glycol (DEG) poisoning**, a notorious cause of mass poisoning when used as an adulterant in pediatric cough syrups or paracetamol elixirs. **Why Option B is Correct:** DEG is metabolized by alcohol dehydrogenase into toxic metabolites (hydroxyethoxyacetic acid). The hallmark triad seen in this patient includes: 1. **Metabolic Derangements:** High Anion Gap Metabolic Acidosis (HAGMA) and an increased Osmolar Gap. 2. **Acute Renal Failure:** Caused by acute tubular necrosis; the presence of **oxalate crystals** in the urine is a key diagnostic clue (similar to ethylene glycol) [1]. 3. **Neurological Involvement:** Encephalopathy and cranial nerve palsies often follow the renal phase [1]. **Why Other Options are Incorrect:** * **A. Paracetamol poisoning:** Primarily causes **centrilobular hepatic necrosis** (jaundice, elevated ALT/AST) [2]. While it can cause renal failure (HRS or ATN), it does not produce oxalate crystals or a significant osmolar gap [2]. * **C. Severe malaria:** Can cause "Blackwater fever" (hemoglobinuria) and renal failure, but it would not explain the increased osmolar gap or oxalate crystalluria. * **D. Hantavirus infection:** Causes Hemorrhagic Fever with Renal Syndrome (HFRS), but the metabolic profile (osmolar gap/oxalate crystals) points specifically to toxic alcohol ingestion. **High-Yield Clinical Pearls for NEET-PG:** * **Antidote:** Fomepizole (inhibits alcohol dehydrogenase) or Ethanol. Hemodialysis is often required [1]. * **The "Gap" Rule:** If a patient has HAGMA + Increased Osmolar Gap + Renal Failure, think **Ethylene Glycol** or **Diethylene Glycol** [1]. * **Oxalate Crystals:** Typically described as "envelope-shaped" (calcium oxalate dihydrate) or "needle-shaped" (monohydrate) [1].
Explanation: **Explanation:** Bupivacaine is a potent long-acting amide local anesthetic known for its significant **cardiotoxicity**. In cases of accidental intravascular injection or systemic toxicity (LAST - Local Anesthetic Systemic Toxicity), bupivacaine binds strongly to cardiac sodium channels and can cause refractory ventricular arrhythmias and severe myocardial depression. **Why Esmolol is the correct answer:** In the management of bupivacaine-induced tachyarrhythmias, **Esmolol** is the preferred agent. It is an ultra-short-acting cardioselective beta-1 blocker. Its rapid onset and very short half-life (approx. 9 minutes) allow for precise titration to control heart rate and hypertension without causing prolonged myocardial depression, which is critical in a heart already compromised by bupivacaine. **Analysis of Incorrect Options:** * **Sotalol:** While a beta-blocker, it also has Class III antiarrhythmic properties (potassium channel blockade) which can prolong the QT interval and worsen the risk of Torsades de Pointes in an unstable toxic heart. * **Lignocaine:** Using another local anesthetic to treat local anesthetic toxicity is contraindicated. Lignocaine would compete for the same sodium channels and exacerbate the CNS and cardiac toxicity. * **5% Dextrose:** This is a crystalloid maintenance fluid with no specific pharmacological role in reversing the membrane-stabilizing effects of bupivacaine. **High-Yield Clinical Pearls for NEET-PG:** * **Gold Standard Treatment:** The definitive treatment for Bupivacaine toxicity is **Intravenous Lipid Emulsion (20% Intralipid)**. It acts as a "lipid sink," sequestering the lipophilic bupivacaine away from cardiac tissue. * **CCB Contraindication:** Calcium channel blockers should be strictly avoided as they worsen bupivacaine-induced myocardial depression. * **Bupivacaine vs. Ropivacaine:** Ropivacaine is an S-enantiomer developed to be less cardiotoxic than bupivacaine.
Explanation: **Explanation:** **Cadmium toxicity** primarily targets the kidneys, specifically the **proximal convoluted tubules (PCT)**. Once absorbed, cadmium binds to a low-molecular-weight protein called **metallothionein**. This complex is filtered by the glomerulus and subsequently reabsorbed by the proximal tubular cells. Inside these cells, cadmium is released, leading to oxidative stress and cell death, resulting in **proximal tubular necrosis**. This manifests clinically as Fanconi-like syndrome (proteinuria, glucosuria, and phosphaturia). **Analysis of Options:** * **A. Proximal tubular necrosis (Correct):** As explained, the PCT is the primary site of cadmium accumulation and damage. Chronic exposure also leads to **Itai-Itai disease**, characterized by osteomalacia and osteoporosis secondary to renal tubular dysfunction. * **B. Distal tubular necrosis:** While severe acute poisoning can cause generalized renal failure, the specific pathological hallmark of cadmium is proximal, not distal, damage. * **C. Asthma:** Cadmium inhalation primarily causes **obstructive lung disease (COPD/Emphysema)** and pulmonary edema, rather than the reversible airway hyperresponsiveness seen in asthma. It is also a known risk factor for lung cancer. * **D. Cirrhosis:** While the liver is an initial storage site for cadmium, the critical organ for chronic toxicity is the kidney. Cirrhosis is more typically associated with chronic arsenic or copper (Wilson’s disease) toxicity. **High-Yield Clinical Pearls for NEET-PG:** * **Itai-Itai Disease:** "Ouch-Ouch" disease; seen in Japan due to cadmium-contaminated rice. * **Biomarker:** Urinary $\beta_2$-microglobulin is a sensitive indicator of cadmium-induced proximal tubular damage. * **Occupational Exposure:** Welding, battery manufacturing (Ni-Cd batteries), and cigarette smoke. * **Antidote:** There is no highly effective chelator for chronic cadmium poisoning; however, **EDTA** may be used in acute cases. Avoid Dimercaprol (BAL) as it can increase nephrotoxicity.
Explanation: Migalastat is a first-in-class pharmacological chaperone therapy approved for the treatment of Fabry’s disease. 1. Why Fabry’s Disease is Correct: Fabry’s disease is an X-linked lysosomal storage disorder caused by a deficiency of the enzyme alpha-galactosidase A (α-Gal A). This leads to the systemic accumulation of globotriaosylceramide (Gb3). In patients with specific "amenable" genetic mutations, the enzyme is produced but is misfolded and unstable. Migalastat works by binding to the active site of these misfolded enzymes, stabilizing them and facilitating their proper trafficking to the lysosome, where they can clear Gb3. Unlike Enzyme Replacement Therapy (ERT), migalastat is administered orally. 2. Why Other Options are Incorrect: * Breast Cancer: Treatment typically involves hormonal therapy (Tamoxifen), HER2 inhibitors (Trastuzumab), or cytotoxic chemotherapy. * Glycogen Storage Disorders (GSD): While GSD II (Pompe disease) is also a lysosomal storage disorder, it is treated with Alglucosidase alfa (ERT), not migalastat. * HIV: Managed with Antiretroviral Therapy (ART) such as Protease Inhibitors, RTIs, and Integrase Inhibitors. High-Yield Clinical Pearls for NEET-PG: * Mechanism: Pharmacological Chaperone (stabilizes α-Gal A). * Route: Oral (significant advantage over IV Enzyme Replacement Therapy). * Indication: Only for patients with amenable mutations (determined by genetic testing). * Fabry’s Disease Triad: Episodic peripheral neuropathy (acroparesthesia), angiokeratomas, and hypohidrosis. Late complications include renal failure and hypertrophic cardiomyopathy.
Principles of Clinical Pharmacology
Practice Questions
Therapeutic Drug Monitoring
Practice Questions
Drug Toxicity and Overdose
Practice Questions
Antidotes and Their Applications
Practice Questions
Management of Drug Poisoning
Practice Questions
Drug-Induced Liver Injury
Practice Questions
Drug-Induced Kidney Injury
Practice Questions
Drug-Induced Blood Dyscrasias
Practice Questions
Drug-Induced QT Prolongation
Practice Questions
Pharmacovigilance
Practice Questions
Get full access to all questions, explanations, and performance tracking.
Start For Free